Chief Scientific Officer Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics Inc (CGEM, Financial) on November 5, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 107,942 shares of the company.
Cullinan Therapeutics Inc (CGEM, Financial) is engaged in the development of oncology and immuno-oncology therapeutics. The company's focus is on developing a diversified pipeline of targeted cancer therapies aimed at treating specific cancers.
On the day of the transaction, shares of Cullinan Therapeutics Inc (CGEM, Financial) were priced at $15.64. This valuation brings the market cap of the company to approximately $903.275 million.
Over the past year, Jennifer Michaelson has sold a total of 90,057 shares and has not purchased any shares. The insider transaction history for Cullinan Therapeutics Inc (CGEM, Financial) shows a trend with 0 insider buys and 18 insider sells over the past year.
For more detailed valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors and analysts can visit the respective links.
This sale by the insider may be of interest to current and potential investors trying to understand the recent activities and stock performance of Cullinan Therapeutics Inc (CGEM, Financial).
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
